Dapsone Use in Dermatology.

Journal

American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290

Informations de publication

Date de publication:
30 Jul 2024
Historique:
accepted: 02 07 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: aheadofprint

Résumé

Dapsone, initially synthesized for textile dyeing, gained recognition in the 1930s for its antibacterial properties, leading to its utilization in dermatology for leprosy and dermatitis herpetiformis. Despite US Food and Drug Administration (FDA) approval for these conditions, dapsone's off-label uses have expanded, making it a valuable option in various dermatologic conditions. This review seeks to highlight the common uses of dapsone in its FDA indications and off-label indications. Diseases in which dapsone is considered first-line therapy or adjunctive therapy are reviewed, with highlights from the resources included. An overview of dapsone's pharmacokinetics, pharmacodynamics, indications, dosages, and safety profile are also reviewed. Dapsone's versatility and safety profile make it a cost-effective treatment option in dermatology, particularly for patients with limited access to specialized medications. Ongoing clinical trials are also described exploring dapsone's efficacy in novel dermatologic uses. Dapsone has been a valuable adjunctive therapy across various dermatologic conditions for years and evidence for its use continues to expand.

Identifiants

DOI: 10.1007/s40257-024-00879-8 PMID: 39078587
pubmed: 39078587
doi: 10.1007/s40257-024-00879-8
pii: 10.1007/s40257-024-00879-8
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103–24. https://doi.org/10.1007/s00403-013-1409-7 .
doi: 10.1007/s00403-013-1409-7 pubmed: 24310318
Wolf R, Matz H, Orion E, Tuzun B, Tuzun Y. Dapsone. Dermatol Online J. 2002. https://doi.org/10.5070/D330M4B5KR .
Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol. 1997;62(6):827–36. https://doi.org/10.1002/jlb.62.6.827 .
doi: 10.1002/jlb.62.6.827 pubmed: 9400824
Fourneau E, Tréfouël J, Nitti F, Bovet D, Tréfouël J, others. Action anti-streptococcique des derives sulfures organiques. CR Acad Sci. 1937;204(7):1763–6.
Faget GH, Pogge RC, Johansen FA, Dinan JF, Prejean BM, Eccles CG. The promin treatment of leprosy. A progress report. Int J Lepr Other Mycobact Dis. 1966;34(3):298–310.
Lang PGJ. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol. 1979;1(6):479–92. https://doi.org/10.1016/s0190-9622(79)80088-2 .
doi: 10.1016/s0190-9622(79)80088-2 pubmed: 528697
Khan F, Roychowdhury S, Nemes R, Vyas P, Woster P, Svensson C. Effect of pro-inflammatory cytokines on the toxicity of the arylhydroxylamine metabolites of sulphamethoxazole and dapsone in normal human keratinocytes. Toxicology. 2006;218(2–3):90–9. https://doi.org/10.1016/j.tox.2005.10.002 .
doi: 10.1016/j.tox.2005.10.002 pubmed: 16289751
Thuong-Nguyen VU, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by daspone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Investig Dermatol. 1993;100(4):349–55. https://doi.org/10.1111/1523-1747.ep12471811 .
Kurien G, Jamil RT, Preuss CV. Dapsone. In: StatPearls. StatPearls Publishing; 2024. Age and gender as predictors of treatment outcomes with once-daily dapsone 7.5% topical gel for acne vulgaris. J Am Acad Dermatol. 2016;4836(15001):A1–A6. https://doi.org/10.1016/j.jaad.2016.02.007 .
Abe M, Shimizu A, Yokoyama Y, Takeuchi Y, Ishikawa O. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-α production from activated mononuclear cells on cutaneous lupus erythematosus. Clin Exp Dermatol. 2008;33(6):759–63. https://doi.org/10.1111/j.1365-2230.2008.02864.x .
doi: 10.1111/j.1365-2230.2008.02864.x pubmed: 18713254
Forks TP. Brown recluse spider bites. J Am Board Fam Med. 2000;13(6):415–23. https://doi.org/10.3122/15572625-13-6-415 .
doi: 10.3122/15572625-13-6-415
Vetter, RS; Swanson DL. Bites of recluse spiders. In: UpToDate, Danzl DF, editor. Wolters Kluwer. Accessed 3 Mar 2024.
Kannan G, Vasantha J, Rani NV, et al. Drug usage evaluation of dapsone. Indian J Pharm Sci. 2009;71(4):456. https://doi.org/10.4103/0250-474X.57301 .
Otberg N, Kang H, Alzolibani AA, Shapiro J. Folliculitis decalvans. Dermatol Ther. 2008;21(4):238–44. https://doi.org/10.1111/j.1529-8019.2008.00204.x .
doi: 10.1111/j.1529-8019.2008.00204.x pubmed: 18715292
Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993;129(5):507–13. https://doi.org/10.1111/j.1365-2133.1993.tb00476.x .
doi: 10.1111/j.1365-2133.1993.tb00476.x pubmed: 8251346
Burke P, Jahangir K, Kolber MR. Dapsone-induced methemoglobinemia: case of the blue lady. Can Fam Physician. 2013;59(9):958–61.
pubmed: 24029511 pmcid: 3771723
Bradberry SM, Vale JA. Multiple-dose activated charcoal: a review of relevant clinical studies. J Toxicol Clin Toxicol. 1995;33(5):407–16. https://doi.org/10.3109/15563659509013749 .
doi: 10.3109/15563659509013749 pubmed: 7650765
Vinod KV, Arun K, Dutta TK. Dapsone hypersensitivity syndrome: a rare life threatening complication of dapsone therapy. J Pharmacol Pharmacother. 2013;4(2):158–60. https://doi.org/10.4103/0976-500X.110917 .
doi: 10.4103/0976-500X.110917 pubmed: 23761718 pmcid: 3669581
UpToDate Lexidrug, Dapsone (systemic). Waltham, MA: UpToDate, Inc. Accessed 27 Mar 2024.
Caproni M, Antiga E, Melani L, Fabbri P, Italian group for cutaneous immunopathology. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol. 2009;23(6):633–8. https://doi.org/10.1111/j.1468-3083.2009.03188.x .
Alexander JO. Dapsone in the treatment of dermatitis herpetiformis. Lancet. 1955;268(6876):1201–2. https://doi.org/10.1016/s0140-6736(55)90693-0 .
Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis. J Clin Investig. 1978;62(1):214–20. https://doi.org/10.1172/JCI109109 .
Anderson R, Gatner EM, van Rensburg CE, et al. In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother. 1981;19(4):495–503. https://doi.org/10.1128/AAC.19.4.495 .
doi: 10.1128/AAC.19.4.495 pubmed: 6264848 pmcid: 181465
Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439.e1-10. https://doi.org/10.1016/j.jaad.2006.10.005 .
doi: 10.1016/j.jaad.2006.10.005 pubmed: 17208334
Stein Gold LF, Jarratt MT, Bucko AD, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(5):553–61.
Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(8):962–9.
Faghihi G, Khosravani P, Nilforoushzadeh MA, et al. Dapsone gel in the treatment of papulopustular rosacea: a double-blind randomized clinical trial. J Drugs Dermatol. 2015;14(6):602–6.
pubmed: 26091386
Ghaoui N, Hanna E, Abbas O, Kibbi A, Kurban M. Update on the use of dapsone in dermatology. Int J Dermatol. 2020;59(7):787–95. https://doi.org/10.1111/ijd.14761 .
doi: 10.1111/ijd.14761 pubmed: 31909480
Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol. 1988;13(2):67–71. https://doi.org/10.1111/j.1365-2230.1988.tb00659.x .
doi: 10.1111/j.1365-2230.1988.tb00659.x pubmed: 2975199
Wollina U, Krönert C, Koch A, Schönlebe J, Vojvodic A, Lotti T. Erythema elevatum diutinum—two case reports, two different clinical presentations, and a short literature review. Open Access Maced J Med Sci. 2019;7(18):3039–42. https://doi.org/10.3889/oamjms.2019.765 .
doi: 10.3889/oamjms.2019.765 pubmed: 31850118 pmcid: 6910801
Katz SI, Gallin JI, Hertz KC, Fauci AS, Lawley TJ. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine (Baltimore). 1977;56(5):443–55.1.
Gulanikar A, Sharma S. A case of erythema elevatum diutinum with dapsone hypersensitivity syndrome. Clin Dermatol Rev. 2019;3(1):92. https://doi.org/10.4103/CDR.CDR_1_18 .
doi: 10.4103/CDR.CDR_1_18
Böer A, Misago N, Wolter M, Kiryu H, Wang XD, Ackerman AB. Prurigo pigmentosa: a distinctive inflammatory disease of the skin. Am J Dermatopathol. 2003;25(2):117–29. https://doi.org/10.1097/00000372-200304000-00005 .
doi: 10.1097/00000372-200304000-00005 pubmed: 12652193
Mufti A, Mirali S, Abduelmula A, et al. Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): a systematic review of the literature. JAAD Int. 2021;3:79–87. https://doi.org/10.1016/j.jdin.2021.03.003 .
doi: 10.1016/j.jdin.2021.03.003 pubmed: 34409375 pmcid: 8362297
Ehmann LM, Meller S, Homey B. Successful treatment of granulomatous rosacea with dapsone. Hautarzt. 2013;64(4):226–8. https://doi.org/10.1007/s00105-013-2556-7 .
doi: 10.1007/s00105-013-2556-7 pubmed: 23576165
Bormann G, Gaber G, Fischer M, Marsch WC. Dapsone in rosacea fulminans. J Eur Acad Dermatol Venereol. 2001;15(5):465–7. https://doi.org/10.1046/j.1468-3083.2001.00325.x .
doi: 10.1046/j.1468-3083.2001.00325.x pubmed: 11763393
Kahn G, Rywlin AM. Acropustulosis of infancy. Arch Dermatol. 1979;115(7):831–3.
doi: 10.1001/archderm.1979.04010070007009 pubmed: 156521
Findlay RF, Odom RB. Infantile acropustulosis. Am J Dis Child. 1983;137(5):455–7. https://doi.org/10.1001/archpedi.1983.02140310037009 .
doi: 10.1001/archpedi.1983.02140310037009 pubmed: 6342363
Dromy R, Raz A, Metzker A. Infantile acropustulosis. Pediatr Dermatol. 1991;8(4):284–7. https://doi.org/10.1111/j.1525-1470.1991.tb00934.x .
doi: 10.1111/j.1525-1470.1991.tb00934.x pubmed: 1792199
Yasuda H, Kobayashi H, Hashimoto T, Itoh K, Yamane M, Nakamura J. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol. 2000;143(1):144–8. https://doi.org/10.1046/j.1365-2133.2000.03604.x .
doi: 10.1046/j.1365-2133.2000.03604.x pubmed: 10886149
Chatterjee M, Meru S, Vasudevan B, Deb P, Moorchung N. Pemphigus foliaceus masquerading as IgA pemphigus and responding to dapsone. Indian J Dermatol. 2012;57(6):495–7. https://doi.org/10.4103/0019-5154.103074 .
doi: 10.4103/0019-5154.103074 pubmed: 23248372 pmcid: 3519261
Moreno ACL, Santi CG, Gabbi TVB, Aoki V, Hashimoto T, Maruta CW. IgA pemphigus: case series with emphasis on therapeutic response. J Am Acad Dermatol. 2014;70(1):200–1. https://doi.org/10.1016/j.jaad.2013.09.037 .
doi: 10.1016/j.jaad.2013.09.037 pubmed: 24355273
Basset N, Guillot B, Michel B, Meynadier J, Guilhou JJ. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol. 1987;123(6):783–5.
doi: 10.1001/archderm.1987.01660300105021 pubmed: 3579359
Aslanova M, Yarrarapu SNS, Zito PM. IgA pemphigus. In: StatPearls. StatPearls Publishing; 2024. Accessed 27 Jan 2024. http://www.ncbi.nlm.nih.gov/books/NBK519063/ .
Bernett CN, Fong M, Yadlapati S, Rosario-Collazo JA. Linear IGA dermatosis. In: StatPearls. StatPearls Publishing; 2024. Accessed 27 Jan 2024. http://www.ncbi.nlm.nih.gov/books/NBK526113/ .
Machado TYS, Enokihara MMSES, Iida TM, Porro AM. Adult linear IgA bullous dermatosis: report of three cases. An Bras Dermatol. 2018;93(3):435–7. https://doi.org/10.1590/abd1806-4841.20187304 .
Shetty VM, Pai SB, Rao R. Linear IgA bullous dermatosis presenting as chronic prurigo: unveiling of the diagnosis by serrated pattern analysis. Int J Dermatol. 2018. https://doi.org/10.1111/ijd.14253 .
Watts PJ, Khachemoune A. Subcorneal pustular dermatosis: a review of 30 years of progress. Am J Clin Dermatol. 2016;17(6):653–71. https://doi.org/10.1007/s40257-016-0202-8 .
doi: 10.1007/s40257-016-0202-8 pubmed: 27349653
Bhargava S, Kumar U, Kroumpouzos G. Subcorneal pustular dermatosis: comprehensive review and report of a case presenting during pregnancy. Int J Womens Dermatol. 2020;6(3):131–6. https://doi.org/10.1016/j.ijwd.2020.02.003 .
doi: 10.1016/j.ijwd.2020.02.003 pubmed: 32637535 pmcid: 7330443
Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol. 1982;6(2):215–23. https://doi.org/10.1016/s0190-9622(82)70014-3 .
doi: 10.1016/s0190-9622(82)70014-3 pubmed: 7037880
Fern AI, Jay JL, Young H, MacKie R. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmol. 1992;76(6):332–5. https://doi.org/10.1136/bjo.76.6.332 .
doi: 10.1136/bjo.76.6.332 pubmed: 1622942 pmcid: 504279
Ciarrocca KN, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(2):159–63. https://doi.org/10.1016/s1079-2104(99)70110-1 .
doi: 10.1016/s1079-2104(99)70110-1 pubmed: 10468458
Hrin ML, Bashyam AM, Feldman SR, Huang WW. Oral dapsone for the treatment of generalized granuloma annulare: a retrospective case series. J Am Acad Dermatol. 2022;86(4):911–4. https://doi.org/10.1016/j.jaad.2021.03.045 .
doi: 10.1016/j.jaad.2021.03.045 pubmed: 33753254
Steiner A, Pehamberger H, Wolff K. Sulfone treatment of granuloma annulare. J Am Acad Dermatol. 1985;13(6):1004–8. https://doi.org/10.1016/s0190-9622(85)70253-8 .
doi: 10.1016/s0190-9622(85)70253-8 pubmed: 3908511
Czarnecki DB, Gin D. The response of generalized granuloma annulare to dapsone. Acta Derm Venereol. 1986;66(1):82–4.
doi: 10.2340/00015555668284 pubmed: 2424227
Saied N, Schwartz RA, Estes SA. Treatment of generalized granuloma annulare with dapsone. Arch Dermatol. 1980;116(12):1345–6.
doi: 10.1001/archderm.1980.01640360019003 pubmed: 7458358
Lindhaus C, Elsner P. Granuloma faciale treatment: a systematic review. Acta Derm Venereol. 2018;98(1):14–8. https://doi.org/10.2340/00015555-2784 .
doi: 10.2340/00015555-2784 pubmed: 28880343
Babalola O, Zhang J, Kristjansson A, Whitaker-Worth D, McCusker M. Granuloma faciale treated with topical dapsone: a case report. Dermatol Online J. 2014;20(8):13030/qt9q7520rx.
Alsorori E, Kiss N, Medvecz M, et al. A case of granuloma faciale successfully treated with systemic dapsone. Dermatol Ther. 2020;33(1): e13162. https://doi.org/10.1111/dth.13162 .
doi: 10.1111/dth.13162 pubmed: 31705567
El Benaye J, Oumakhir S, Ghfir M, Sedrati O. Dapsone efficacy in lupus miliaris disseminatus faciei: two cases. Ann Dermatol Venereol. 2011;138(8–9):597–600. https://doi.org/10.1016/j.annder.2011.02.019 .
doi: 10.1016/j.annder.2011.02.019 pubmed: 21893234
Çerman AA, Karabay EA, Yalçın Ö, Altunay IK. Lupus miliaris disseminatus faciei: a case report and brief literature review. Sisli Etfal Hastan Tip Bul. 2018;52(2):142–4. https://doi.org/10.14744/SEMB.2017.39306 .
doi: 10.14744/SEMB.2017.39306 pubmed: 32595389 pmcid: 7315059
Al-Mutairi N. Nosology and therapeutic options for lupus miliaris disseminatus faciei. J Dermatol. 2011;38(9):864–73. https://doi.org/10.1111/j.1346-8138.2011.01244.x .
doi: 10.1111/j.1346-8138.2011.01244.x pubmed: 21714812
Kumano K, Tani M, Murata Y. Dapsone in the treatment of miliary lupus of the face. Br J Dermatol. 1983;109(1):57–62. https://doi.org/10.1111/j.1365-2133.1983.tb03992.x .
doi: 10.1111/j.1365-2133.1983.tb03992.x pubmed: 6860572
Schmidt E, Reimer S, Kruse N, Bröcker EB, Zillikens D. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol. 2002;124(1):157–62. https://doi.org/10.1046/j.1365-2249.2001.01503.x .
doi: 10.1046/j.1365-2249.2001.01503.x
Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol. 2009;10(6):383–96. https://doi.org/10.2165/11310740-000000000-00000 .
doi: 10.2165/11310740-000000000-00000 pubmed: 19824739
Schmidt E, Kraensel R, Goebeler M, et al. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis. 2005;76(3):205–9.
pubmed: 16268266
Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34(4):683–4. https://doi.org/10.1016/s0190-9622(96)80085-5 .
doi: 10.1016/s0190-9622(96)80085-5 pubmed: 8601662
Jeffes EW 3rd, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol. 1989;14(2):132–6. https://doi.org/10.1111/j.1365-2230.1989.tb00910.x .
doi: 10.1111/j.1365-2230.1989.tb00910.x pubmed: 2689016
Werth VP, Fivenson D, Pandya AG, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25–32. https://doi.org/10.1001/archderm.144.1.25 .
doi: 10.1001/archderm.144.1.25 pubmed: 18209165 pmcid: 7382893
Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2005;141(6):699–702. https://doi.org/10.1001/archderm.141.6.699 .
doi: 10.1001/archderm.141.6.699 pubmed: 15967915
Haim S, Birnbaum F. Dapsone in the treatment of pemphigus vulgaris. Dermatology. 1978;156(2):120–3. https://doi.org/10.1159/000250907 .
doi: 10.1159/000250907
Lepe K, Yarrarapu SNS, Zito PM. Pemphigus foliaceus. In: StatPearls. StatPearls Publishing; 2024.
Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol. 1976;94(6):681–6. https://doi.org/10.1111/j.1365-2133.1976.tb05168.x .
doi: 10.1111/j.1365-2133.1976.tb05168.x pubmed: 779820
Connor B. Herpetiform pemphigus foliaceus responsive to dapsone. Br J Dermatol. 1972;86(1):99–101. https://doi.org/10.1111/j.1365-2133.1972.tb01903.x .
doi: 10.1111/j.1365-2133.1972.tb01903.x pubmed: 5060427
Leibowitz MR, Voss SP. Juvenile pemphigus foliaceous: response to dapsone. Arch Dermatol. 1993;129(7):910.
doi: 10.1001/archderm.1993.01680280100026 pubmed: 8323319
Galambrun C, Cambazard F, Clavel C, Versini P, Stephan JL. Pemphigus foliaceus. Arch Dis Child. 1997;77(3):255–7. https://doi.org/10.1136/adc.77.3.255 .
doi: 10.1136/adc.77.3.255 pubmed: 9370909 pmcid: 1717309
Mehravaran M, Moln ÁR, et al. Juvenile pemphigus foliaceus: juvenile pemphigus foliaceus. Br J Dermatol. 1998;139(3):496–99. https://doi.org/10.1046/j.1365-2133.1998.02417.x .
Cianchini G, Lembo L, Colonna L, Puddu P. Pemphigus foliaceus induced by radiotherapy and responsive to dapsone. J Dermatol Treat. 2006;17(4):244–6. https://doi.org/10.1080/09546630600921197 .
doi: 10.1080/09546630600921197
Khachemoune A, Guldbakke KK, Ehrsam E. Pemphigus foliaceus: a case report and short review. Cutis. 2006;78(2):105–10.
pubmed: 16983898
Demirçay Z, Baykal C, Demirkesen C. Lichen planus pemphigoides: report of two cases. Int J Dermatol. 2001;40(12):757–9. https://doi.org/10.1046/j.1365-4362.2001.01334.x .
doi: 10.1046/j.1365-4362.2001.01334.x pubmed: 11903670
Falk DK, Latour DL, King LE. Dapsone in the treatment of erosive lichen planus. J Am Acad Dermatol. 1985;12(3):567–70. https://doi.org/10.1016/s0190-9622(85)70080-1 .
doi: 10.1016/s0190-9622(85)70080-1 pubmed: 3989015
Ellis E, Scheinfeld N. Eosinophilic pustular folliculitis: a comprehensive review of treatment options. Am J Clin Dermatol. 2004;5(3):189–97. https://doi.org/10.2165/00128071-200405030-00007 .
doi: 10.2165/00128071-200405030-00007 pubmed: 15186198
Takematsu H. Eosinophilic pustular folliculitis: report of two cases with a review of the Japanese literature. Arch Dermatol. 1985;121(7):917. https://doi.org/10.1001/archderm.1985.01660070107029 .
doi: 10.1001/archderm.1985.01660070107029 pubmed: 4015140
Steffen C. Eosinophilic pustular folliculitis (Ofuji’s disease) with response to dapsone therapy. Arch Dermatol. 1985;121(7):921–3.
doi: 10.1001/archderm.1985.01660070111030 pubmed: 4015141
Malanin G, Helander I. Eosinophilie pustular folliculitis (Ofuji’s disease): response to dapsone but not to isotretinoin therapy. J Am Acad Dermatol. 1989;20(6):1121. https://doi.org/10.1016/S0190-9622(89)80190-2 .
doi: 10.1016/S0190-9622(89)80190-2 pubmed: 2666460
Anjaneyan G, Manne S, Panicker VV, Eapen M. Ofuji’s disease in an immunocompetent patient successfully treated with dapsone. Indian Dermatol Online J. 2016;7(5):399–401. https://doi.org/10.4103/2229-5178.190497 .
doi: 10.4103/2229-5178.190497 pubmed: 27730038 pmcid: 5038103
Smith LC, Cox NH. Dapsone treatment for eosinophilic fasciitis. Arch Dermatol. 2008;144(7):845–7. https://doi.org/10.1001/archderm.144.7.845 .
doi: 10.1001/archderm.144.7.845 pubmed: 18645135
Bokotas C, Kouris A, Stefanaki C, Sgotzou T, Christofidou E, Kontochristopoulos G. Wells syndrome: response to dapsone therapy. Ann Dermatol. 2014;26(4):541. https://doi.org/10.5021/ad.2014.26.4.541 .
doi: 10.5021/ad.2014.26.4.541 pubmed: 25143695 pmcid: 4135121
Caputo R, Marzano AV, Vezzoli P, Lunardon L. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol. 2006. https://doi.org/10.1001/archderm.142.9.1157 .
Coelho de Sousa V, Laureano Oliveira A, Cardoso J. Successful treatment of eosinophilic cellulitis with dapsone. Dermatol Online J. 2016;22(7):13030/qt9v67b10b.
Wallis L, Gilson RC, Gilson RT. Dapsone for recalcitrant eosinophilic annular erythema: a case report and literature review. Dermatol Ther (Heidelb). 2018;8(1):157–63. https://doi.org/10.1007/s13555-017-0214-1 .
doi: 10.1007/s13555-017-0214-1 pubmed: 29222624
Manriquez J, Berroeta‐Mauriziano D, Andino‐Navarrete R, Vera‐Kellet C. Eosinophilic annular erythema: complete clinical response with dapsone. Int J Dermatol. 2015. https://doi.org/10.1111/ijd.12736 .
Liang SE, Hoffmann R, Peterson E, Soter NA. Use of dapsone in the treatment of chronic idiopathic and autoimmune urticaria. JAMA Dermatol. 2019;155(1):90. https://doi.org/10.1001/jamadermatol.2018.3715 .
doi: 10.1001/jamadermatol.2018.3715 pubmed: 30476976
Morgan M, Cooke A, Rogers L, Adams-Huet B, Khan DA. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol In Prac. 2014;2(5):601–6. https://doi.org/10.1016/j.jaip.2014.06.004 .
doi: 10.1016/j.jaip.2014.06.004
Engin B, Özdemir M. Prospective randomized non‐blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. Acad Dermatol Venereol. 2008;22(4):481–6. https://doi.org/10.1111/j.1468-3083.2007.02510.x .
Nutan F, Ortega-Loayza AG. Cutaneous lupus: a brief review of old and new medical therapeutic options. J Investig Dermatol Sympos Proc. 2017;18(2):S64–8. https://doi.org/10.1016/j.jisp.2017.02.001 .
doi: 10.1016/j.jisp.2017.02.001
Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011;13(4):300–7. https://doi.org/10.1007/s11926-011-0180-z .
doi: 10.1007/s11926-011-0180-z pubmed: 21503694 pmcid: 3245840
Klebes M, Wutte N, Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatology. 2016;232(1):91–6. https://doi.org/10.1159/000441054 .
doi: 10.1159/000441054 pubmed: 26606129
Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica. 1986;172(4):214–7. https://doi.org/10.1159/000249338 .
doi: 10.1159/000249338 pubmed: 3519302
Neri R, Mosca M, Bernacchi E, Bombardieri S. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone. Lupus. 1999;8(3):240–3. https://doi.org/10.1191/096120399678847713 .
doi: 10.1191/096120399678847713 pubmed: 10342718
Pate DA, Johnson LS, Tarbox MB. Leukocytoclastic vasculitis resolution with topical dapsone. Cutis. 2017;99(6):426–8.
pubmed: 28686752
Nürnberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol. 1995;75(1):54–6. https://doi.org/10.2340/00015555755456 .
doi: 10.2340/00015555755456 pubmed: 7747536
Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143(2):458–66. https://doi.org/10.1016/j.jaci.2018.09.007 .
doi: 10.1016/j.jaci.2018.09.007 pubmed: 30268388
Kechichian E, Haber R, Mourad N, El Khoury R, Jabbour S, Tomb R. Pediatric pyoderma gangrenosum: a systematic review and update. Int J Dermatol. 2017;56(5):486–95. https://doi.org/10.1111/ijd.13584 .
doi: 10.1111/ijd.13584 pubmed: 28233293
Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea. 2007;26(2):215–9. https://doi.org/10.1097/ICO.0b013e31802eb078 .
doi: 10.1097/ICO.0b013e31802eb078 pubmed: 17251816
Din RS, Tsiaras WG, Li DG, Mostaghimi A. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review. J Drugs Dermatol. 2018;17(10):1058–60.
pubmed: 30365585
Kaur S, Gupta D, Garg B, Sood N. Neutrophilic dermatosis of dorsal hands. Indian Dermatol Online J. 2015;6(1):42–5. https://doi.org/10.4103/2229-5178.148940 .
doi: 10.4103/2229-5178.148940 pubmed: 25657918 pmcid: 4314889
Micallef D, Bonnici M, Pisani D, Boffa MJ. Neutrophilic dermatosis of the dorsal hands: a review of 123 cases. J Am Acad Dermatol. 2023;88(6):1338–44. https://doi.org/10.1016/j.jaad.2019.08.070 .
doi: 10.1016/j.jaad.2019.08.070 pubmed: 31499154
Galaria NA, Junkins-Hopkins JM, Kligman D, James WD. Neutrophilic dermatosis of the dorsal hands: pustular vasculitis revisited. J Am Acad Dermatol. 2000;43(5):870–4. https://doi.org/10.1067/mjd.2000.109286 .
doi: 10.1067/mjd.2000.109286 pubmed: 11050599
DiCaudo DJ, Connolly SM. Neutrophilic dermatosis (pustular vasculitis) of the dorsal hands: a report of 7 cases and review of the literature. Arch Dermatol. 2002. https://doi.org/10.1001/archderm.138.3.361 .
Ramos FS, Ferreira FR, Rabay FMDO, Lira MLDA. Neutrophilic dermatosis of the dorsal hands: response to dapsone monotherapy. An Bras Dermatol. 2018;93(5):730–2. https://doi.org/10.1590/abd1806-4841.20187488 .
doi: 10.1590/abd1806-4841.20187488 pubmed: 30156627 pmcid: 6106668
Gillihan R, Farahbakhsh N, Motaparthi K. Neutrophilic urticarial dermatosis without underlying systemic disease. J Clin Aesthet Dermatol. 2020;13(3):20–1.
pubmed: 32308792 pmcid: 7159310
Gusdorf L, Lipsker D. Neutrophilic urticarial dermatosis: a review. Ann Dermatol Vénéréol. 2018;145(12):735–40. https://doi.org/10.1016/j.annder.2018.06.010 .
doi: 10.1016/j.annder.2018.06.010 pubmed: 30224079
Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine. 2009;88(1):23–31. https://doi.org/10.1097/MD.0b013e3181943f5e .
doi: 10.1097/MD.0b013e3181943f5e pubmed: 19352297
Cohen PR. Sweet’s syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2(1):34. https://doi.org/10.1186/1750-1172-2-34 .
doi: 10.1186/1750-1172-2-34 pubmed: 17655751 pmcid: 1963326
Aram H. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Response to dapsone. Arch Dermatol. 1984;120(2):245–7.
doi: 10.1001/archderm.1984.01650380105023 pubmed: 6696481
Mahajan VK, Sharma NL, Sharma RC. Sweet’s syndrome from an Indian perspective: a report of four cases and review of the literature. Int J Dermatol. 2006;45(6):702–8. https://doi.org/10.1111/j.1365-4632.2006.02622.x .
doi: 10.1111/j.1365-4632.2006.02622.x pubmed: 16796632
Shibata K, Tateishi T, Yamasaki R, Ohyagi Y, Kira J. Successful treatment of a case of steroid-dependent neuro-Sweet disease with dapsone. Rinsho Shinkeigaku. 2010;50(4):257–61. https://doi.org/10.5692/clinicalneurol.50.257 .
Keisham C, Sarkar R, Garg V, Chugh S. Ashy dermatosis in an 8-year-old Indian child. Indian Dermatol Online J. 2013;4(1):30. https://doi.org/10.4103/2229-5178.105466 .
doi: 10.4103/2229-5178.105466 pubmed: 23439983 pmcid: 3573449
Bahadir S, Çobanoglu Ü, Çimsit G, Yayli S, Alpay K. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol. 2004;43(3):220–2. https://doi.org/10.1111/j.1365-4632.2004.01984.x .
doi: 10.1111/j.1365-4632.2004.01984.x pubmed: 15009398
Correspondence G-Y. Int J Dermatol. 1998;37(10):796–8. https://doi.org/10.1046/j.1365-4362.1998.00522.x .
doi: 10.1046/j.1365-4362.1998.00522.x
Nguyen K, Khachemoune A. Ashy dermatosis: a review. Dermatol Online J. 2019;25(5):13030/qt44f462s8.
Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29(5):267–79. https://doi.org/10.1111/j.1346-8138.2002.tb00263.x .
doi: 10.1111/j.1346-8138.2002.tb00263.x pubmed: 12081158
Mangelsdorf HC, White WL, Jorizzo JL. Behçet’s disease. J Am Acad Dermatol. 1996;34(5):745–50. https://doi.org/10.1016/S0190-9622(96)90006-7 .
doi: 10.1016/S0190-9622(96)90006-7 pubmed: 8632067
Jacyk WK. Behçet’s disease in South African blacks: report of five cases. J Am Acad Dermatol. 1994;30(5):869–73. https://doi.org/10.1016/S0190-9622(94)70102-4 .
doi: 10.1016/S0190-9622(94)70102-4 pubmed: 8169265
Estève C, Samson M, Guilhem A, et al. Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: a retrospective study of 42 patients. Kuwana M, ed. PLoS ONE. 2017;12(10):e0187296. https://doi.org/10.1371/journal.pone.0187296 .
Durand JM, Lefèvre P, Hovette P, Mongin M, Soubeyrand J. Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients. Br J Haematol. 1991;78(3):459–60. https://doi.org/10.1111/j.1365-2141.1991.tb04467.x .
doi: 10.1111/j.1365-2141.1991.tb04467.x pubmed: 1873232
Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults—a report on 90 patients. Eur J Haematol. 2005;75(4):328–31. https://doi.org/10.1111/j.1600-0609.2005.00545.x .
doi: 10.1111/j.1600-0609.2005.00545.x pubmed: 16146539
Godeau B, Durand J, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997;97(2):336–9. https://doi.org/10.1046/j.1365-2141.1997.412687.x .
doi: 10.1046/j.1365-2141.1997.412687.x pubmed: 9163598
Paquet P, Piérard GE. Traitement par dapsone de la folliculite décalvante. Ann Dermatol Vénéréol. 2004;131(2):195–7. https://doi.org/10.1016/S0151-9638(04)93570-3 .
doi: 10.1016/S0151-9638(04)93570-3 pubmed: 15026749
Broussard KC, Berger TG, Rosenblum M, Murase JE. Erosive pustular dermatosis of the scalp: a review with a focus on dapsone therapy. J Am Acad Dermatol. 2012;66(4):680–6. https://doi.org/10.1016/j.jaad.2011.10.011 .
doi: 10.1016/j.jaad.2011.10.011 pubmed: 22074698
Feramisco J, George T, Schulz S, Ma H, Metze D, Steinhoff M. Disseminated erosive pustular dermatosis also involving the mucosa: successful treatment with oral dapsone. Acta Derm Venerol. 2012;92(1):91–2. https://doi.org/10.2340/00015555-1162 .
doi: 10.2340/00015555-1162 pubmed: 21681355
Di Bartolomeo L, Ceravolo I, Borgia F, Vaccaro F, Guarneri C, Vaccaro M. Treatment of erosive pustular dermatosis of the scalp: our experience and review of unconventional topical drugs. Eur Rev Med Pharmacol Sci. 2023;27(3):1023–6. https://doi.org/10.26355/eurrev_202302_31197 .
doi: 10.26355/eurrev_202302_31197 pubmed: 36808348
Karanfilian KM, Wassef C. Erosive pustular dermatosis of the scalp: causes and treatments. Int J Dermatol. 2021;60(1):25–32. https://doi.org/10.1111/ijd.14955 .
doi: 10.1111/ijd.14955 pubmed: 32516510
Junejo MH, Kentley J, Rajpopat M, Tan XL, Mohd Mustapa MF, Harwood CA. Therapeutic options for erosive pustular dermatosis of the scalp: a systematic review*. Br J Dermatol. 2021;184(1):25–33. https://doi.org/10.1111/bjd.19026 .
doi: 10.1111/bjd.19026 pubmed: 32163590
Rabindranathnambi A, Jeevankumar B. Dapsone in hidradenitis suppurativa: a systematic review. Dermatol Ther (Heidelb). 2022;12(2):285–93. https://doi.org/10.1007/s13555-021-00674-x .
doi: 10.1007/s13555-021-00674-x pubmed: 34997914 pmcid: 8850499
Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GBE. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222(4):342–6. https://doi.org/10.1159/000329023 .
doi: 10.1159/000329023 pubmed: 21757878
López-Llunell C, Riera-Martí N, Gamissans M, Romaní J. Dapsone in hidradenitis suppurativa: a case series of 56 patients. Dermatol Ther. 2021;34(6): e15161. https://doi.org/10.1111/dth.15161 .
doi: 10.1111/dth.15161 pubmed: 34665504
Murray G, Hollywood A, Kirby B, Hughes R. Dapsone therapy for hidradenitis suppurativa. Br J Dermatol. 2020;183(4):767–8. https://doi.org/10.1111/bjd.19136 .
doi: 10.1111/bjd.19136 pubmed: 32294243
Baroudi B, Bashyam AM, Feldman SR, Pichardo RO. Dapsone to treat moderate-to-severe hidradenitis suppurativa: a retrospective case-series. J Drugs Dermatol. 2023;22(11):e12–6. https://doi.org/10.36849/JDD.4936 .
doi: 10.36849/JDD.4936 pubmed: 37943259

Auteurs

Katie K Lovell (KK)

Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA. kennedyka20@students.ecu.edu.

Rushan I Momin (RI)

Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA.

Harneet Singh Sangha (HS)

Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA.

Steven R Feldman (SR)

Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA.
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Rita O Pichardo (RO)

Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA.
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Classifications MeSH